On July 21, 2022 Bristol Myers Squibb NYSE (BMY) reported the first biopharma three-year exclusive collaboration with the premier African American Family Organization, Jack and Jill of America, Inc. to inspire more Black and African American individuals to join the biopharma industry to assist in creating more equity and better health outcomes for all patients through student engagement (Press release, Bristol-Myers Squibb, JUL 21, 2022, View Source [SID1234616844]). The strategic alliance is an extension of BMS’ Tomorrow’s Innovators Historically Black College (HBCU) initiative launched with the goal of creating a sustainable bridge of talent to the biopharma industry from the HBCU community and aligns with BMS’s inclusion and diversity health equity commitments to increase workforce representation by creating and sustaining a pipeline of diverse talent.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The collaboration will commence at Jack and Jill’s bi-annual 45th National Convention "The Power of a Dream" from July 26-31 in Orlando, Fla., where BMS will be the exclusive biopharma sponsor. The 2022 National Convention will exemplify the power of dreaming and significance of helping children to dream by featuring an interactive legacy gallery of notable Jack and Jill of America alumni in entertainment, business, government, education, media, technology, and social justice, among other industries. BMS will be involved in several events during the convention, including the flagship Programming Luncheon, the Mothers "Closing the Gap: Health, Wealth, and Wellness Forums and Expo" centered around addressing health inequities in the healthcare system and improving healthcare support for communities of color, a virtual career fair and an in-person booth engagement.

"We are so excited to join forces with such a historically prestigious organization like Jack and Jill of America, Inc., to further both of our missions to empower the Black youth to go after their dreams. We hope those dreams include joining the biopharma industry for young Black students," said Shamika Williams, senior director of HBCU initiatives at Bristol Myers Squibb. "In the biopharma industry, there is an immediate need for more diverse representation as it informs the future of medical advancements and resources that directly affect and serve minority communities. We are thrilled to be poised to help bridge this equity gap along with other influential leaders in the space."

"This inaugural collaboration opens the doors for Black and African American youth to learn about opportunities in the biopharma industry," said Kornisha McGill Brown, national president of Jack and Jill of America, Inc. "More representation in the industry helps to drive innovation, which is critical now more than ever to fight inequality in our current health system and to help people and communities achieve better health equity."

On July 21, 2022 BridgeBio Pharma, Inc. (Nasdaq: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, reported a new collaboration with Baylor College of Medicine to identify and translate cutting-edge research into potential therapies for patients with genetic diseases (Press release, BridgeBio, JUL 21, 2022, View Source [SID1234616843]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"In these challenging times we believe it is more important than ever to be a stalwart partner to academic institutions working to serve patient populations big and small. We look forward to developing a close partnership with scientists at Baylor College of Medicine, which is known for its productive research engine, in the hope of translating innovations into meaningful medicines for patients with unmet medical needs," said Neil Kumar, Ph.D., BridgeBio founder and CEO.

Baylor College of Medicine’s unique approach to therapeutic development for genetic diseases and precision oncology integrates basic, translational and clinical sciences. Through this collaboration, BridgeBio will work with Baylor College of Medicine to identify and translate promising innovations into potential therapies for patients with genetically driven diseases.

"Together with BridgeBio’s drug development team, we are optimistic that our interdisciplinary team of scientists and physicians will be able to develop new therapeutics for patients in need and further our mission to identify and develop drugs for a wide variety of diseases," said Joseph Petrosino, Ph.D., chief scientific innovation officer and chair and professor of molecular virology & microbiology at Baylor.

A core part of BridgeBio’s efforts to help patients is the identification of new discoveries in academia. Through its academic collaborations, BridgeBio seeks to revolutionize the relationships between the drug development industry and biomedical researchers by moving away from one-off interactions in favor of engaging and creative partnerships. For a list of some of BridgeBio’s academic partners, please visit Our Partners page.

On July 21, 2022 BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) reported that the company will report its second quarter 2022 financial results Thursday, August 4, 2022 (Press release, BioCryst Pharmaceuticals, JUL 21, 2022, View Source [SID1234616842]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

BioCryst management will host a conference call and webcast at 8:30 a.m. ET that day to discuss the financial results and provide a corporate update.

The live call may be accessed by dialing 866-374-5140 for domestic callers and 404-400-0571 for international callers and using conference ID 68509725#. A live webcast of the call and any slides will be available online at the investors section of the company website at www.biocryst.com. A replay of the call will be available on the company website.

On July 21, 2022 Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, reported that the Company will provide a corporate and financial update for the second quarter 2022 on Thursday, July 28, 2022, before the market opens (Press release, Athenex, JUL 21, 2022, View Source [SID1234616841]). Athenex’s management team will host a conference call and live audio webcast at 8:00 a.m. Eastern Time.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To participate in the call, dial either the domestic or international number fifteen minutes before the conference call begins:

The live conference call and replay can also be accessed via audio webcast here and on the Investor Relations section of the Company’s website under "Events and Presentations", located at View Source

On June 21, 2022 Anixa Biosciences, Inc. (NASDAQ: ANIX) ("Anixa"), a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, reported that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance broadening protection of Anixa’s novel breast cancer vaccine technology, which has been exclusively licensed from, and is being developed in partnership with, Cleveland Clinic (Press release, Anixa Biosciences, JUL 21, 2022, View Source [SID1234616840]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The patent is titled, "Breast Cancer Vaccine," and the lead inventor is Dr. Vincent Tuohy of the Department of Inflammation and Immunity at Cleveland Clinic’s Lerner Research Institute. This patent is in the family of the originally granted patent, and it covers additional intellectual property related to Anixa’s breast cancer vaccine technology.

"We are pleased to receive this notice of allowance from the USPTO, confirming additional protection of the breast cancer vaccine technology," stated Dr. Amit Kumar, Chairman and CEO of Anixa. "This breast cancer vaccine has the potential to prevent Triple Negative Breast Cancer ("TNBC"), the deadliest form of breast cancer, and perhaps other forms of breast cancer that express alpha-lactalbumin. With our partners at Cleveland Clinic, we are currently performing clinical testing of this vaccine, and hope to have preliminary results by year end."

About Triple-Negative Breast Cancer
One in eight women in the U.S. will be diagnosed with an invasive breast cancer at some point in their lives. Approximately 10-15% of those diagnoses are TNBC, however TNBC accounts for a disproportionately higher percentage of breast cancer deaths and has a higher rate of recurrence. This form of breast cancer is twice as likely to occur in African-American women, and approximately 70% to 80% of the breast tumors that occur in women with mutations in the BRCA1 genes are triple-negative breast cancer.

About Anixa Bioscience’s Breast Cancer Vaccine
Anixa’s investigational vaccine, currently in Phase 1 trials, takes advantage of endogenously produced proteins that have a function at certain times in life, but then become "retired" and disappear from the body. One such protein is a breast-specific lactation protein, α-lactalbumin, which is no longer found post-lactation in normal, aging tissues, but is present in the majority of triple-negative breast cancers. Activating the immune system against this "retired" protein provides preemptive immune protection against emerging breast tumors that express α-lactalbumin. The vaccine also contains an adjuvant that activates an innate immune response, which allows the immune system to mount a response against emerging tumors to prevent them from growing.